EuropaBio Announces Finalists for Most Innovative European Biotech SME Awards 2017
EuropaBio, the European Association for Bioindustries, today announces the finalists for 8th edition of the Most Innovative European Biotech SME Awards, which recognizes innovative biotech SMEs and the crucial role they play in answering some of society’s greatest challenges.
Twenty-five small and medium biotech companies contended for this year’s awards, with five of them shortlisted by the Jury to compete across three categories: healthcare, industrial and agricultural biotechnology. They will be showcased during a pitching session, followed by an awards ceremony hosted by Awards Jury Member and MEP Paul Rubig at the European Parliament in Brussels, Belgium on November 22.
The five shortlisted SMEs are:
Healthcare/“Red Biotech” Category
Nightingale Health, a Finnish biotechnology company addressing chronic diseases with a proprietary blood analysis platform that can improve risk prediction of, among others, cardiovascular diseases and diabetes.
NovaBiotics, a UK-based clinical-stage biotechnology company focused on the design and development of first-in-class anti-infectives for difficult-to-treat, medically unmet diseases.
Industrial/“White Biotech” Category
Carbios, a French green chemistry company focused on discovering and developing enzymatic bioprocesses to reinvent the lifecycle of plastics.
Numaferm, a German spin-off company from the Institute of Biochemistry of the Heinrich-Heine-University in Düsseldorf that has developed a reliable, cost-efficient technology to manufacture peptides based on well-designed microorganisms that convert simple nutrients to peptides.
Agricultural/ “Green Biotech” Category
Iden Biotechnology, a Spanish company developing biotech products and integrated solutions for crop yield and quality enhancement, including agrobiological products (e.g. plant biostimulants and biopesticides), and more productive crop varieties.
Visit the awards website to read more about the awards, the jury and the rules.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Pfizer, GSK Gain ACIP Recommendations for RSV and Meningococcal Vaccines
April 18th 2025The Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices voted to expand access to Pfizer’s respiratory syncytial virus vaccine Abrysvo for high-risk adults in their 50s and voted in favor of GSK’s meningococcal vaccine, Penmenvy, for streamlined adolescent protection.
